A phase III single arm study to evaluate the efficacy, safety and local tolerability of a subcutaneous 3?month formulation of triptorelin pamoate (11.25�mg) in patients with locally advanced or metastatic prostate cancer.
Read time: 1 mins
Last updated:9th Oct 2012
To confirm the efficacy of triptorelin pamoate (11.25 mg)prolonged release (PR) formulation by inducing castration (defined as serum testosterone level of <50 ng/dL or <1.735 nmol/L) at Day 29 and maintaining castration at Day 183 (after receiving two subcutaneous (s.c.) administrations of triptorelin pamoate, 3 months apart).
|Study start date||2012-10-09|